SCHEMBL1366388

SCHEMBL1366388

Cc1nc(-c2ccccc2)ncc1C(=O)NC1CCN(Cc2ccccc2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.63
PRKAB2 O43741 2/20 0.60
PRKAG1 P54619 2/20 0.60
PRKAA2 P54646 2/20 0.60
PRKAA1 Q13131 2/20 0.60
PRKAG3 Q9UGI9 2/20 0.60
PRKAG2 Q9UGJ0 2/20 0.60
PRKAB1 Q9Y478 2/20 0.60
SLC6A12 P48065 3/20 0.59
DRD4 P21917 2/20 0.58
SIGMAR1 Q99720 3/20 0.57
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
SLC6A13 Q9NSD5 1/20 0.55
LMNA P02545 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
JAK2 O60674 1/20 0.55
JAK1 P23458 1/20 0.55
TYK2 P29597 1/20 0.55
JAK3 P52333 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1367494 0.89 SLC6A12 (0.62) POLBPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL1366822 0.88 DRD4 (0.60) POLBPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL1364923 0.86 DGAT1 (0.53) PRKAA1KMT2AJAK3MAPK1
SCHEMBL14094525 0.86 DGAT1 (0.53) POLBMEN1KMT2ALMNASMN1; SMN2
SCHEMBL1366534 0.84 PRKAA2 (0.75) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL1366703 0.84 DGAT1 (0.55) POLBSMN1; SMN2CYP3A4
SCHEMBL1367559 0.83 DGAT1 (0.51) DRD4CYP3A4CYP2D6
SCHEMBL4406616 0.83 KDM4E (0.58) MEN1KMT2ALMNASMN1; SMN2TSHR
SCHEMBL1364239 0.82 DGAT1 (0.48) MEN1KMT2ALMNASMN1; SMN2TSHR
SCHEMBL1367633 0.77 DRD4 (0.61) POLBPRKAB2PRKAG1PRKAA2PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067589-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2011-11-29 US disclosed
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions BLAKE TANISHA D 2009-11-12 US disclosed
US-7582643-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2009-09-01 US disclosed
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions BLAKE TANISHA D 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions CYP11B2, CYP11B1, LTC4S POLB 2811/4885PRKAB2 4386/4885PRKAG1 4286/4885
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions CYP11B2, CYP11B1, LTC4S POLB 2811/4885PRKAB2 4386/4885PRKAG1 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.